论文部分内容阅读
目的探讨溶血磷脂酸(LPA)及糖类抗原125(CA125)在卵巢癌不同临床分期中的表达情况及对卵巢癌的监测价值。方法回顾性分析2013年1-12月广州市第一人民医院收治的112例不同临床分期卵巢癌患者的LPA和CA125含量,同时选择同期68例卵巢良性肿瘤及60例正常体检女性的血浆LPA和CA125作为对照。结果良性肿瘤组和正常体检组的LPA和CA125值均低于卵巢癌组(P<0.05);卵巢癌患者Ⅰ-Ⅲ期患者LPA水平随着临床分期由早到晚呈现上升趋势(P<0.05),但Ⅲ期和Ⅳ期间差异无统计学意义(P=0.128)。CA125水平也随着临床分期由早到晚呈现上升趋势(P<0.05)。此外,卵巢癌患者LPA阳性率要高于CA125阳性率,差异有统计学意义(χ2=5.956,P=0.015)。结论 LPA与CA125均可作为卵巢癌的监测指标,LPA在卵巢癌检测中具有更高的敏感性。
Objective To investigate the expression of lysophosphatidic acid (LPA) and carbohydrate antigen 125 (CA125) in different clinical stages of ovarian cancer and its value of monitoring ovarian cancer. Methods The data of LPA and CA125 levels in 112 patients with different clinical stage of ovarian cancer admitted to the First People’s Hospital of Guangzhou from January to December in 2013 were retrospectively analyzed. Meanwhile, the plasma LPA and the serum levels of LPA in 68 cases of ovarian benign tumor and 60 normal women CA125 as a control. Results The LPA and CA125 values of benign tumor group and normal group were lower than those of ovarian cancer group (P <0.05). The LPA level of patients with stage Ⅰ-Ⅲ ovarian cancer increased from morning to evening with clinical stage (P0.05 ), But there was no significant difference between stage Ⅲ and stage Ⅳ (P = 0.128). The level of CA125 also increased with the clinical stage from morning to night (P <0.05). In addition, the positive rate of LPA in ovarian cancer patients was higher than that of CA125, the difference was statistically significant (χ2 = 5.956, P = 0.015). Conclusions Both LPA and CA125 can be used as monitoring indicators in ovarian cancer, and LPA has higher sensitivity in detecting ovarian cancer.